UK – First UK patients receive experimental mRNA therapy for cancer in global trial

The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359

Imperial College Healthcare NHS Trust (ICHT) and Imperial College London (ICL) have announced that the first UK patients have received the experimental mRNA therapy in an ongoing phase 1/2 clinical trial to treat melanoma, lung cancer and other solid tumour cancers.

The patients received the treatment at the National Institute for Health and Care Research’s Imperial Clinical Research facility at Hammersmith Hospital.

In the UK, around one in two people will be diagnosed with cancer in their lifetime. While a range of therapies, including chemotherapy and immune therapies, have been successful, some cancer cells can become resistant to drugs, making tumours more challenging to treat…